1. Home
  2. STG vs XLO Comparison

STG vs XLO Comparison

Compare STG & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunlands Technology Group

STG

Sunlands Technology Group

HOLD

Current Price

$3.16

Market Cap

46.0M

Sector

Real Estate

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$8.33

Market Cap

49.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STG
XLO
Founded
2003
2016
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.0M
49.8M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
STG
XLO
Price
$3.16
$8.33
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
4.2K
32.4K
Earning Date
05-21-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$168.77
P/E Ratio
$1.10
N/A
Revenue Growth
N/A
589.88
52 Week Low
$2.97
$0.46
52 Week High
$15.00
$9.25

Technical Indicators

Market Signals
Indicator
STG
XLO
Relative Strength Index (RSI) 42.63 55.05
Support Level N/A $0.62
Resistance Level $3.59 $8.66
Average True Range (ATR) 0.21 0.49
MACD 0.02 -0.05
Stochastic Oscillator 26.39 49.38

Price Performance

Historical Comparison
STG
XLO

About STG Sunlands Technology Group

Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: